Pfizer has presented results from two phase 3 trials evaluating the efficacy and safety of Litfulo (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.
In the two studies, Litfulo 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation compared to placebo.
These improvements were supported by patient-reported outcomes indicating reduced disease severity and meaningful change in facial and total body vitiligo, as well as greater disease stabilisation compared to placebo.
These results from the largest phase 3 programme to date evaluating an oral systemic therapy for nonsegmental vitiligo (NSV) were presented today in a late-breaking oral presentation at the 35th European Academy of Dermatology and Venereology (EADV) Annual Congress in Vienna, Austria.
Pfizer intends to submit these data to regulatory authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for review.
